Posts

Gilead Acquires Ouro Medicines for Up to $2.18 Billion to Advance T Cell Engager Autoimmune Therapies

on

Astellas and Vir Biotechnology Announce $1.7B Collaboration for VIR-5500 Prostate Cancer Drug, Including $240M Cash Upfront

on

AbbVie Partners with China's Zelgen on DLL3-Targeted T-Cell Engager ZG006 in Up-to-$1.2B Deal

on

Cartography Biosciences Closes $67 Million Series B Round Led by Pfizer to Advance CRC T-cell Engager

on

Zymeworks Halts Development of ZW171 T-cell Engager After Phase 1 Trial Assesses Benefit-Risk Profile

on

AbbVie and Genmab Move to Expand Use of T Cell Engager Epkinly Following Strong Phase III Results

on

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

on

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

on